4CPS-039 Allantoin 6% cream in epidermolysis bullosa: a case report

Background Epidermolysis bullosa (EB) is a clinically and genetically heterogeneous group of skin fragility disorders characterised by trauma-induced blister formation for which there is no definitive therapy. Wound care is an important component of management. Allantoin acts as an emollient, healing and protecting the wounds, and applied topically. Purpose Demonstrate safety and efficacy of Alantoin 6% in EB. Material and methods Observational, retrospective and descriptive study of a patient with EB in a third-tier hospital. The information has been obtained from the Electronic Clinical History (SELENE ® ) and the Pharmacy Service Managing Software (FARMATOOLS ® ). Results Patient: 5 years’ old female with EB. Treatments reported to date include corticosteroids, antihistamines, amitriptyline and mupirocin. However, control of inflammation has not demostrated consistent efficacy. The girl was included in a clinical study with allantoin 6% cream in May 2017. Treatment with formulation containing 6% allantoin has demonstrated an improvement in the girl’s wounds. Conclusion Allantoin 6% quickened the wounds’ healing and furthermore it was associated with an acceptable safety profile. We need more studies to evaluate the efficacy and safety of Allantoin 6% in patients with EB. References and/or Acknowledgements Data sheet allantoin, SELENE®, FARMATOOLS®, Efficacy and Safety of SD-101 Cream in Patients with Epidermolysis Bullosa: Results From a Phase 2b Study No conflict of interest